|1.||Trepanier, Lauren A: 2 articles (01/2010 - 05/2006)|
|2.||Mendel, Ralf R: 1 article (10/2014)|
|3.||Havemeyer, Antje: 1 article (10/2014)|
|4.||Kunze, Thomas: 1 article (10/2014)|
|5.||Clement, Bernd: 1 article (10/2014)|
|6.||Bittner, Florian: 1 article (10/2014)|
|7.||Krischkowski, Carmen: 1 article (10/2014)|
|8.||Plitzko, Birte: 1 article (10/2014)|
|9.||Ott, Gudrun: 1 article (10/2014)|
|10.||Reichmann, Debora: 1 article (10/2014)|
10/01/1993 - "In 12 subjects studied prospectively, SMX-HA cytotoxicity was also significantly greater in those with subsequent hypersensitivity. "
10/01/1993 - "The cytotoxicity of SMX-HA to PBMC was significantly greater in the 22 HIV-infected patients with prior hypersensitivity than both the 23 HIV-infected patients without hypersensitivity and the control group. "
10/20/2014 - "Investigations with the heterologously expressed human mARC-2 protein showed a higher catalytic efficiency toward SMX-HA than mARC-1, but none of the investigated human protein variants showed statistically significant differences of its N-reductive activity and was therefore likely to participate in the pathogenesis of hypersensitivity reaction under treatment with SMX. "
05/01/2006 - "This suggests that SMX-NO cytotoxicity may be mediated, at least in part, by redox cycling between SMX-HA and SMX-NO. Overall, these data indicate that endogenous ascorbate and glutathione are important for the intracellular reduction of SMX-NO, a proposed mediator of SMX hypersensitivity, and that redox cycling of SMX-HA to SMX-NO may contribute to the cytotoxicity of these metabolites in vitro."
05/01/1998 - "Hypersensitivity reactions from trimethoprim/sulfamethoxazole are likely caused by a reactive nitroso intermediate formed from sulfamethoxazole hydroxylamine. "
10/01/2004 - "Therefore the goal of this study was to determine the effect of fluconazole, clarithromycin, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with HIV-1 infection. "
10/01/2004 - "The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283)."
10/01/1993 - "Given that fever is often a prominent feature of hypersensitivity, we also assessed whether SMX or SMX-HA could induce the in vitro production of IL-1 beta, IL-6 or tumour necrosis factor-alpha (TNF-alpha) by PBMC. "
12/01/1990 - "Compounds implicated in both drug-induced necrosis (N-acetyl-p-benzoquinone imine; NAPQI) and drug hypersensitivity (sulfamethoxazole hydroxylamine; SMX-HA) were examined and their effects on [Ca2+]i compared with those of the T cell mitogen phytohemagglutinin (PHA; 1.5 micrograms/ml) and the calcium ionophore ionomycin (2.5 microM). "
|4.||Drug Toxicity (Drug Safety)
10/01/2004 - "Sulfamethoxazole hydroxylamine formation, in combination with long-term oxidative stress, is thought to be the cause of high rates of adverse drug reactions to sulfamethoxazole in human immunodeficiency virus (HIV)-infected subjects. "
09/01/1995 - "Variation in the formation and disposition of the hydroxylamine of (SMX-HA) is thought to play an important role in the pathogenesis of sulfamethoxazole (SMX)-induced idiosyncratic adverse drug reactions. "
|5.||Acquired Immunodeficiency Syndrome (AIDS)
08/15/2001 - "A decreased ability to reduce SMX-HA to SMX could predispose patients with systemic activation of host defense mechanisms, such as those with AIDS, to the occurrence of SMX-associated adverse reactions."
08/01/1994 - "This is the first report of the formation and excretion of sulfamethoxazole hydroxylamine in patients with acquired immunodeficiency syndrome. "
08/01/1994 - "We measured the urine concentrations of sulfamethoxazole, sulfamethoxazole hydroxylamine, and N-sulfamethoxazole on days 3 and 10 in 15 patients with acquired immunodeficiency syndrome treated with a combination product of trimethoprim (15 mg/kg/day) and sulfamethoxazole (75 mg/kg/day). "
|5.||Hydroxylamine (Hydroxylamine Hydrochloride)
|7.||Trimethoprim-Sulfamethoxazole Combination (Co-Trimoxazole)
|9.||Glutathione (Reduced Glutathione)
|10.||Interleukin-1beta (Interleukin 1 beta)